

IN THE CLAIMS

Please amend claims 3-9 to read as follows:

3.(amended) The transdermal patch of claim 1 wherein the percutaneous absorption enhancer is polyoxyethylene oleyl ether and/or isopropyl myristate.

4.(amended) The ophthalmic transdermal patch of claim 1 wherein the content of polyoxyethylene oleyl ether in the drug-containing layer is 5-30 W/W%.

5.(amended) The ophthalmic transdermal patch of claim 3 wherein the content of isopropyl myristate in the drug-containing layer is 5-30 W/W%.

6.(amended) The ophthalmic transdermal patch of claim 1 wherein the base matrix comprises acrylic adhesive, silicone elastomer or styrene-isoprene-styrene copolymer.

7.(amended) The ophthalmic transdermal patch of claim 3 wherein the ratio of the content by weight concentration (W/W%) of polyoxyethylene oleyl ether to isopropyl myristate is in the range of 1:0.1-1:5 in the drug-containing layer.

8.(amended) The ophthalmic transdermal patch of claim 1 wherein the drug is a steroidal drug.

9.(amended) The ophthalmic transdermal patch of claim 1 wherein the drug is a compound of the formula (1)